Project Details
| Short title | VT3996-301 |
|---|---|
| Acronym | VT3996-301 |
| Status | Active |
| Effective start/end date | 21/06/22 → 27/04/27 |
CTU: An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
- Park, John (Primary Chief Investigator)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research